Comment from UCB, Inc.
AnonymousSupportBusiness
Summary: UCB, Inc., a biopharmaceutical company, supports the FDA's initiative to leverage existing pharmacologic knowledge for drug repurposing to accelerate treatment for unmet medical needs. The company specifically advocates for the repurposing of Brivaracetam and Certolizumab Pegol for various neurologic and autoimmune conditions, citing their established safety profiles and scientific rationale.
Please see the attached comment submitted on behalf of UCB, Inc. Thank you.